Approximately 50% of NSCLC with KRAS mutations have additional co-accompanied mutations that are critical in tumorigenesis, such as TP53, STK11/LKB1, KEAP1, and SAMARCA4—which are the most commonly reported mutations (109). This evidence concerns the gene TP53 and non-small cell lung carcinoma.